RVNC Stock Overview
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Revance Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.79 |
| 52 Week High | US$37.98 |
| 52 Week Low | US$3.63 |
| Beta | 1.09 |
| 1 Month Change | -23.12% |
| 3 Month Change | -33.04% |
| 1 Year Change | -88.34% |
| 3 Year Change | -86.37% |
| 5 Year Change | -71.67% |
| Change since IPO | -85.88% |
Recent News & Updates
Recent updates
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You
Mar 04
Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain
Feb 29Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%
Dec 28Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be
Nov 10Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt
Aug 10Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors
Jun 14Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Apr 17Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Jan 02Revance Therapeutics submits sBLA for Daxxify for cervical dystonia
Oct 20Revance climbs 14% as FDA approves facial injectable for frown lines
Sep 08Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems
Aug 24Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Aug 04Revance: Potential Comeback On FDA Resubmission For DAXI
Jul 15Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Apr 17Shareholder Returns
| RVNC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -14.6% | -2.3% | -3.7% |
| 1Y | -88.3% | 11.4% | 20.2% |
Return vs Industry: RVNC underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: RVNC underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| RVNC volatility | |
|---|---|
| RVNC Average Weekly Movement | 13.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RVNC's share price has been volatile over the past 3 months.
Volatility Over Time: RVNC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 597 | Mark Foley | www.revance.com |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage.
Revance Therapeutics, Inc. Fundamentals Summary
| RVNC fundamental statistics | |
|---|---|
| Market cap | US$394.98m |
| Earnings (TTM) | -US$323.99m |
| Revenue (TTM) | US$234.04m |
1.7x
P/S Ratio-1.2x
P/E RatioIs RVNC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVNC income statement (TTM) | |
|---|---|
| Revenue | US$234.04m |
| Cost of Revenue | US$152.16m |
| Gross Profit | US$81.88m |
| Other Expenses | US$405.86m |
| Earnings | -US$323.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.11 |
| Gross Margin | 34.98% |
| Net Profit Margin | -138.43% |
| Debt/Equity Ratio | -283.0% |
How did RVNC perform over the long term?
See historical performance and comparison